Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Inclusion Criteria: * Type 2 diabetes mellitus * Diet-treated subjects with type 2 diabetes with HbA1c 7.5-9.5 % * Subjects with type 2 diabetes in oral anti-diabetic drug (OAD) monotherapy treated with metformin or alpha-glucosidase inhibitors with HbA1c 7.0-9.5% * Body mass index (BMI) 18.5-40 kg/m\^2 * Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator) Exclusion Criteria: * Impaired liver function * Impaired renal function * Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure * Any clinically significant abnormal ECG (electrocardiogram) * Uncontrolled treated/untreated hypertension * Recurrent severe hypoglycaemia as judged by the Investigator * Active hepatitis B and/or active hepatitis C * Positive human immunodeficiency virus (HIV) antibodies * Known or suspected allergy to trial product(s) or related products